NASDAQ: COAGHemab Therapeutics Holdings Inc Stock
$40.11-0.36 (-0.89%)
Updated Sep 15, 2026
COAG Price
$40.11
Fair Value Price
$3.16
Market Cap
$1.87B
52 Week Low
$23.00
52 Week High
$55.42
P/E
N/A
P/B
4.12x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.03
Operating Cash Flow
N/A
Beta
1.73
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
COAG Overview
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine COAG's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
COAG
Ranked#179 of 461
Ranked#179 of 461
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.25 | A | |
| $42.17 | A | |
| $110.82 | A |
Be the first to know about important COAG news, forecast changes, insider trades & much more!
COAG News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how COAG scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
COAG ($40.11) is overvalued by 1,168.8% relative to our estimate of its Fair Value price of $3.16 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
COAG ($40.11) is not significantly undervalued (1,168.8%) relative to our estimate of its Fair Value price of $3.16 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
COAG is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more COAG due diligence checks available for Premium users.
Valuation
COAG fair value
Fair Value of COAG stock based on Discounted Cash Flow (DCF)
Price
$40.11
Fair Value
$3.16
Overvalued by
1,168.80%
COAG ($40.11) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
COAG ($40.11) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
COAG price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.12x
Industry
5.24x
COAG is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
COAG's financial health
Profit margin
Revenue
$0.0
Net Income
-$24.2M
Profit Margin
0%
Assets to liabilities
Assets
$467.8M
Liabilities
$13.5M
Debt to equity
0.03
COAG's short-term assets ($464.00M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
COAG's short-term assets ($464.00M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
COAG's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$22.6M
Investing
-$107.4M
Financing
$317.6M
COAG vs Biotech Stocks
Hemab Therapeutics Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.